SLC5A2 and type 2 diabetes mellitus: Introduced as a new class of drugs for the treatment of type 2 diabetes, SGLT2 inhibitors (e.g., dapagliflozin, canagliflozin, empagliflozin) inhibit the reabsorption of glucose in the kidney, leading to glycosuria.